Table 2.

Oncogenic aberration and PD‐L1 expression in 130 consecutive NSCLC patients

	PD‐L1 expression
Type of mutation	PD‐L1 < 1% (n = 42)	1% ≤ PD‐L1 < 50% (n = 59)	PD‐L1 ≥ 50% (n = 29)	P †
EGFR, N (%)
Negative	26 (61.9)	45 (76.3)	26 (89.7)	0.051‡ 0.031 §
Positive	16 (38.1)	14 (23.7)	3 (10.3)
Exon 19 deletion	5 (11.9)	6 (9.0)	2 (10.5)
Exon 21 L858R	7 (16.7)	4 (2.6)	0 (0.0)
Others	4 (9.5)	4 (0.7)	1 (5.3)
ALK, N (%)
Negative	41 (97.6)	55 (93.2)	27 (93.1)	0.652‡ 0.427§
Positive	1 (2.4)	4 (6.8)	2 (6.9)
ROS1, N (%)
Negative	42 (100.0)	58 (98.3)	26 (89.7)	0.031 ‡ 0.304§
Positive	0 (0.0)	1 (1.7)	3 (10.3)

^† P was evaluated by comparison with the wild type gene.

^‡ PD‐L1 < 50% versus PD‐L1 ≥ 50%.

^§ PD‐L1 < 1% versus PD‐L1 ≥ 1%.

Values in bold are statistically significant.